ADMA injures the glomerular filtration barrier: Role of nitric oxide and superoxide

American Journal of Physiology - Renal Physiology

Volumn 296, Issue 6, 2009, Pages

  Sharma, Mukut ^a   Zhou, Zongmin ^b   Miura, Hiroto ^a   Papapetropoulos, Andreas ^b   McCarthy, Ellen T ^c   Sharma, Ram ^d   Savin, Virginia J ^a   Lianos, Elias A ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cardiorenal disease; Chronic kidney disease

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ALBUMIN; APOCYNIN; CYCLIC GMP; CYCLIC GMP DERIVATIVE; GUANYLATE CYCLASE ACTIVATOR; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUPEROXIDE; TEMPOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; GLOMERULUS EPITHELIUM; GLOMERULUS FILTRATION BARRIER; KIDNEY INJURY; MALE; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; RAT; RISK REDUCTION;

EID: 66449130085     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.90369.2008     Document Type: Article

References (56)

1. Araujo M, Welch WJ. Oxidative stress and nitric oxide in kidney function. Curr Opin Nephrol Hypertens 15: 72-77, 2006. (Pubitemid 43755837)
2. Baylis C. Nitric oxide deficiency; both consequence and cause of chronic renal disease (CRD). Hypertens Nephrol 5: 193-201, 2001.
3. Chen M, Li Y, Yang T, Wang Y, Bai Y, Xie X. ADMA induces monocyte adhesion via activation of chemokine receptors in cultured THP-1 cells. Cytokine 43: 149-159, 2008.
4. Cross JM, Donald A, Vallance PJ, Deanfield JE, Woolfson RG, MacAllister RJ. Dialysis improves endothelial function in humans. Nephrol Dial Transplant 16: 1823-1829, 2001. (Pubitemid 32821414)
5. Dileepan KN, Ram S, Stechschulte DJ, Savin VJ. Effect of superoxide on albumin permeability of isolated rat glomeruli. J Lab Clin Med 121: 797-804, 1993. (Pubitemid 23175875)
6. Druhan LJ, Forbes SP, Pope AJ, Chen CA, Zweier JL, Cardounel AJ. Regulation of eNOS-derived superoxide by endogenous methylarginines. Biochemistry 47: 7256-7263, 2008.
7. Ferrario R, Takahashi K, Fogo A, Badr KF, Munger KA. Consequences of acute nitric oxide synthesis inhibition in experimental glomerulonephritis. J Am Soc Nephrol 4: 1847-1854, 1994. (Pubitemid 24976988)
8. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113: 1708-1714, 2006. (Pubitemid 43754233)
9. G, dimethyl-L-arginine and their reersibility by vasodilators in conscious rats. Br J Pharmacol 110: 1457-1464, 1993.
10. Giugliano D, Ceriello A, Paolisso G. Diabetes mellitus, hypertension and cardiovascular disease: which role for oxidative stress? Metabolism 44: 363-368, 1995.
11. Greiber S, Münzel T, Kästner S, Müller B, Schollmeyer P, Pavenstädt H. NAD(P)H oxidase activity in cultured human podocytes: effects of adenosine triphosphate. Kidney Int 53: 654-663, 1998.
12. Griffith OW, Stuehr DJ. Nitric oxide syntheses: properties and catalytic mechanism. Annu Rev Physiol 57: 707-736, 1995.
13. Herrera M, Garvin JL. Recent advances in the regulation of nitric oxide in the kidney. Hypertension 45: 1062-1067, 2005. (Pubitemid 40770304)
14. Heumuller S, Wind S, Barbosa-Sicard E, Schmidt HH, Busse R, Schroder K, Brandes RP. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 51: 211-217, 2008.
15. Homer KL, Wanstall JC. Cyclic GMP-independent relaxation of rat pulmonary artery by spermine NONOate, a diazeniumdiolate nitric oxide donor. Br J Pharmacol 131: 673-682, 2000.
16. Huie RE, Padmaja S. The reaction of NO with superoxide. Free Radic Res Commun 18: 195-199, 1993.
17. Ischiropoulos H. Biological selectivity and functional aspects of protein tyrosine nitration. Biochem Biophys Res Commun 305: 776-783, 2003. (Pubitemid 36581936)
18. Jacobi J, Maas R, Cordasic N, Koch K, Schmieder RE, Böger RH, Hilgers KF. Role of asymmetric dimethylarginine for angiotensin IIinduced target organ damage in mice. Am J Physiol Heart Circ Physiol 294: H1058-H1066, 2008.
19. Jones SA, Hancock JT, Jones OT, Neubauer A, Topley N. The expression of NADPH oxidase components in human glomerular mesangial cells: detection of protein and mRNA for p47phox, p67phox, and p22phox. J Am Soc Nephrol 5: 1483-1491, 1995.
20. Keefer LK, Flippen-Anderson JL, George C, Shanklin AP, Dunams TM, Christodoulou D, Saavedra JE, Sagan ES, Bohle DS. Chemistry of the diazeniumdiolates. I. Structural and spectral characteristics of the N(O)NO functional group. Nitric Oxide 5: 377-394, 2001.
21. Kielstein JT, Impraim B, Simmel S, Bode-Böger SM, Tsikas D, Frölich JC, Hoeper MM, Haller H, Fliser D. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109: 172-177, 2004. (Pubitemid 38114135)
22. Kojima H, Nakatsubo N, Kikuchi K, Kawahara S, Kirino Y, Nagoshi H, Hirata Y, Nagano T. Detection and imaging of nitric oxide with novel fluorescent indicators: diaminofluoresceins. Anal Chem 70: 2446-2453, 1998. (Pubitemid 128501019)
23. Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care 30: 1834-1839, 2007. (Pubitemid 47036360)
24. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 43: 542-548, 1999. (Pubitemid 29369253)
25. MacAllister R, Whitley GS, Vallance P. Effects of guanidino and uremic compounds on nitric oxide pathways. Kidney Int 45: 737-742, 1994. (Pubitemid 24094485)
26. McAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 11: 2449-2452, 1996. (Pubitemid 27033779)
27. McCarthy ET, Sharma R, Sharma M, Li JZ, Ge XL, Dileepan KN, Savin VJ. TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol 9: 433-438, 1998. (Pubitemid 28122868)
28. McCarty MF. Vascular endothelium is the organ chiefly responsible for the catabolism of plasma asymmetric dimethylarginine-an explanation for the elevation of plasma ADMA in disorders characterized by endothelial dysfunction. Med Hypotheses 63: 699-708, 2004. (Pubitemid 39485844)
29. Mitchell JA, Hecker M, Anggård EE, Vane JR. Cultured endothelial cells maintain their L-arginine level despite the continuous release of EDRF. Eur J Pharmacol 182: 573-576, 1990. (Pubitemid 20260779)
30. Moens AL, Kass DA. Therapeutic potential of tetrahydrobiopterin for treating vascular and cardiac disease. J Cardiovasc Pharmacol 50: 238-246, 2007. (Pubitemid 47428970)
31. Morris SM Jr. Arginine: beyond protein. Am J Clin Nutr 83: 508S-512S, 2006.
32. Mount PF, Power DA. Nitric oxide in the kidney: functions and regulation of synthesis. Acta Physiol (Oxf) 187: 433-446, 2006.
33. Mundel P, Gambaryan S, Bachmann S, Koesling D, Kriz W. Immunolocalization of soluble guanylyl cyclase subunits in rat kidney. Histochem Cell Biol 103: 75-79, 1995.
34. Nanayakkara PWB, Teerlink T, Stehouwer CDA, Allajar D, Spijkerman A, Schalkwijk C, Ter Wee PM, Van Guldener C. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-tomoderate renal failure. Kidney Int 68: 2230-2236, 2005. (Pubitemid 43117798)
35. Olken NM, Marletta MA. NG-methyl-L-arginine functions as an alternate substrate and mechanism-based inhibitor of nitric oxide synthase. Biochemistry 32: 9677-9685, 1993. (Pubitemid 23296812)
36. G-dimethylarginine dimethylaminohydrolase and protein arginine N-methyltransferase isoforms in diabetic rat kidney: effects of angiotensin II receptor blockers. Diabetes 57: 172-180, 2008.
37. Pou S, Keaton L, Surichamorn W, Rosen GM. Mechanism of superoxide generation by neuronal nitric oxide synthase. J Biol Chem 274: 9573-9580, 1999. (Pubitemid 129517933)
38. Poulos TL. Soluble guanylate cyclase. Curr Opin Struct Biol 16: 736-743, 2006. (Pubitemid 44834471)
39. Priviero FB, Baracat JS, Teixeira CE, Claudino MA, De Nucci G, Antunes E. Mechanisms underlying relaxation of rabbit aorta by BAY 41-2272, a nitric oxide-independent soluble guanylate cyclase activator. Clin Exp Pharmacol Physiol 32: 728-734, 2005. (Pubitemid 41603152)
40. Savin VJ, Sharma R, Lovell HB, Welling DJ. Measurement of albumin reflection coefficient with isolated rat glomeruli. J Am Soc Nephrol 3: 1260-1269, 1992.
41. Scalera F, Martens-Lobenhoffer J, Bukowska A, Lendeckel U, Täger M, Bode-Böger SM. Effect of telmisartan on nitric oxide-asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging. Hypertension 51: 696-703, 2008.
42. Schopfer FJ, Baker PR, Freeman BA. NO-dependent protein nitration: a cell signaling event or an oxidative inflammatory response? Trends Biochem Sci 28: 646-654, 2003. (Pubitemid 37500899)
43. Shah SV. The role of reactive oxygen metabolites in glomerular disease. Annu Rev Physiol 57: 245-262, 1995.
44. Sharma M, Sharma R, McCarthy ET, Savin VJ. The focal segmental glomerulosclerosis permeability factor: biochemical characteristics and biological effects. Exp Biol Med 229: 85-98, 2004. (Pubitemid 38101683)
45. Sharma M, McCarthy ET, Savin VJ, Lianos EA. Nitric oxide preserves the glomerular protein permeability barrier by antagonizing superoxide. Kidney Int 68: 2735-2744, 2005. (Pubitemid 43251018)
46. Smith CL, Anthony S, Hubank M, Leiper JM, Vallance P. Effects of ADMA upon gene expression: an insight into the pathophysiological significance of raised plasma ADMA. PLoS Med 2: e264, 2005. (Pubitemid 41549954)
47. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, Schröder H, Schroeder W, Stahl E, Steinke W, Straub A, Schramm M. NOindependent regulatory site on soluble guanylate cyclase. Nature 410: 212-215, 2001. (Pubitemid 32216593)
48. Stolk J, Hiltermann TJ, Dijkman JH, Verhoeven AJ. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir Cell Mol Biol 11: 95-102, 1994.
49. Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, Nakata S, Tsujimoto T, Toyohira Y, Hayashida Y, Sasaguri Y, Ueta Y, Nakashima Y, Yanagihara N. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 24: 1682-1688, 2004. (Pubitemid 39180895)
50. Tojo A, Welch WJ, Bremer V, Kimoto M, Kimura K, Omata M, Ogawa T, Vallance P, Wilcox CS. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 52: 1593-1601, 1997. (Pubitemid 28032063)
51. Tran CTL, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atherosclerosis Suppl 4: 3-40, 2003. (Pubitemid 38234493)
52. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575, 1992.
53. Veresh Z, Racz A, Lotz G, Koller A. ADMA impairs nitric oxidemediated arteriolar function due to increased superoxide production by angiotensin II-NAD(P)H oxidase pathway. Hypertension 52: 960-966, 2008.
54. Williams HC, Griendling KK. NADPH oxidase inhibitors: new antihypertensive agents? J Cardiovasc Pharmacol 50: 9-16, 2007. (Pubitemid 47220441)
55. Yada T, Kaji S, Akasaka T, Mochizuki S, Ogasawara Y, Tanemoto K, Yoshida K, Kajiya F. Changes of asymmetric dimethylarginine, nitric oxide, tetrahydrobiopterin, and oxidative stress in patients with acute myocardial infarction by medical treatments. Clin Hemorheol Microcirc 37: 269-276, 2007. (Pubitemid 350032245)
56. Zhao Y, Brandish PE, Schelvis JPM, DiValentin M, Babcock GT, Marletta MA. Inhibition of soluble guanylate cyclase by ODQ. Biochemistry 39: 10848-10854, 2000.